2011
Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis
Strober B, Crowley J, Yamauchi P, Olds M, Williams D. Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. British Journal Of Dermatology 2011, 165: 661-668. PMID: 21574984, DOI: 10.1111/j.1365-2133.2011.10419.x.Peer-Reviewed Original ResearchConceptsPhysician global assessmentPlacebo-treated patientsProportion of patientsWeek 12Severe psoriasisWeeks 0Tumor necrosis factor-α antagonists etanerceptCo-primary efficacy endpointsSevere chronic plaque psoriasisSeverity Index (PASI) 75 responseGlobal assessmentEffective psoriasis therapiesEffective psoriasis treatmentEtanercept-treated patientsPASI 75 responseChronic plaque psoriasisPhase II studySerious adverse eventsPhase IIIEfficacy endpointPlacebo injectionsPlaque psoriasisAdverse eventsII studyPsoriasis Area
2007
Alefacept for the treatment of psoriasis and other dermatologic diseases
Strober B, Menon K. Alefacept for the treatment of psoriasis and other dermatologic diseases. Dermatologic Therapy 2007, 20: 270-276. PMID: 17970892, DOI: 10.1111/j.1529-8019.2007.00140.x.Peer-Reviewed Original ResearchConceptsT cellsSeverity Index (PASI) 75 responseMemory effector T cellsNovel biologic agentsLong-term remissionEffector T cellsTreatment of psoriasisAntigen presenting cellsPathophysiology of psoriasisCourse of therapyDimeric fusion proteinPASI 75Plaque psoriasisAdverse eventsPsoriasis AreaBiologic agentsMore patientsLabel useImmunologic activationPresenting cellsIntramuscular injectionDosing strategiesAlefaceptDermatologic diseasesPsoriasis